Reviewing Synergy Pharmaceuticals (SGYP) and Its Peers
Synergy Pharmaceuticals (NASDAQ: SGYP) is one of 292 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its competitors? We will compare Synergy Pharmaceuticals to related companies based on the strength of its earnings, risk, dividends, valuation, institutional ownership, profitability and analyst recommendations.
Volatility & Risk
Synergy Pharmaceuticals has a beta of 1064.55, indicating that its share price is 106,355% more volatile than the S&P 500. Comparatively, Synergy Pharmaceuticals’ competitors have a beta of 6.66, indicating that their average share price is 566% more volatile than the S&P 500.
This is a breakdown of current recommendations and price targets for Synergy Pharmaceuticals and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Synergy Pharmaceuticals Competitors||739||2971||11061||223||2.72|
Synergy Pharmaceuticals currently has a consensus target price of $8.90, indicating a potential upside of 168.07%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 30.64%. Given Synergy Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Synergy Pharmaceuticals is more favorable than its competitors.
Institutional and Insider Ownership
71.5% of Synergy Pharmaceuticals shares are held by institutional investors. Comparatively, 50.8% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 3.8% of Synergy Pharmaceuticals shares are held by insiders. Comparatively, 17.0% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
This table compares Synergy Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Synergy Pharmaceuticals Competitors||-5,527.67%||-454.17%||-42.49%|
Valuation & Earnings
This table compares Synergy Pharmaceuticals and its competitors top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Synergy Pharmaceuticals||$2.41 million||-$216.83 million||-2.86|
|Synergy Pharmaceuticals Competitors||$258.58 million||$65.85 million||-7.43|
Synergy Pharmaceuticals’ competitors have higher revenue and earnings than Synergy Pharmaceuticals. Synergy Pharmaceuticals is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
About Synergy Pharmaceuticals
Synergy Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s product candidates include TRULANCE (plecanatide) and dolcanatide. The Company is engaged in the discovery, research and development efforts around analogs of uroguanylin for the treatment of GI diseases and disorders. TRULANCE is designed to replicate the function of uroguanylin. Dolcanatide is being evaluated for inflammatory bowel disease (IBD). TRULANCE is approved in the United States under the trademark name TRULANCE, for the treatment of adults with chronic idiopathic constipation (CIC). In addition, it is developing TRULANCE for the treatment of adults with irritable bowel syndrome with constipation (IBS-C). Dolcanatide is designed to be an analog of uroguanylin with enhanced resistance to standard digestive breakdown by proteases in the intestine.
Receive News & Ratings for Synergy Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synergy Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.